Previous 10 | Next 10 |
home / stock / mrna / mrna articles
As the U.S. launches a fresh round of updated COVID-19 vaccines, some patients encounter hurdles in obtaining prompt health insurance coverage...
The Nasdaq 100 closed slightly higher on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could ...
Moderna, Inc. (NASDAQ: MRNA) shares are trading lower Monday alongside other vaccine stocks amid a selloff after the sector gained amid r...
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. Scilex Holding Company (NASDAQ: SCLX)...
New COVID-19 boosters have been approved by the U.S. FDA in the fight against new variants. A new survey showed how likely people are to get n...
Moderna, Inc. (NASDAQ: MRNA) shares are trading higher after the EMA Committee for Medicinal Products for Human Use adopted an opinion recommending...
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respi...
Wall Street edged higher during Wednesday’s midday session, despite the August CPI report showing the annual inflation rate rising to 3.7%, a...
Financial Times Europe Set To Launch Anti-Subsidy Probe Into Chinese Electric Vehicles Chinese electric vehicle company stocks, including XPe...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...